SIRNAOMICS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.3 HKD | +3.96% |
|
+8.62% | -82.40% |
| Sales 2023 | - | Sales 2024 * | 2M 15.66M 160M | Capitalization | 69.87M 547M 5.6B |
|---|---|---|---|---|---|
| Net income 2023 | -78M -611M -6.25B | Net income 2024 * | -124M -971M -9.93B | EV / Sales 2023 | - |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 34.9 x |
| P/E ratio 2023 |
-4.45
x | P/E ratio 2024 * |
-0.57
x | Employees | 145 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 81.24% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +3.96% | ||
| 1 week | +8.62% | ||
| Current month | -25.27% | ||
| 1 month | -29.61% | ||
| 3 months | -79.45% | ||
| 6 months | -86.88% | ||
| Current year | -82.40% |
1 week
5.64
6.50
1 month
5.648.78
Current year
5.6436.00
1 year
5.6459.00
3 years
5.64101.00
5 years
5.64101.00
10 years
5.64101.00
| Managers | Title | Age | Since |
|---|---|---|---|
Patrick Lu
CEO | Chief Executive Officer | 68 | 14/10/20 |
Wing Kei Yip
DFI | Director of Finance/CFO | 39 | 30/09/18 |
David Evans
CTO | Chief Tech/Sci/R&D Officer | 61 | 11/07/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Feng Mao Hua
BRD | Director/Board Member | 56 | 30/11/21 |
Patrick Lu
CEO | Chief Executive Officer | 68 | 14/10/20 |
David Evans
CTO | Chief Tech/Sci/R&D Officer | 61 | 11/07/21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.50% | 4 M€ | -27.92% | ||
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 6.3 | +3.96% | 4,413,850 |
| 25/04/24 | 6.06 | +3.24% | 4,938,950 |
| 24/04/24 | 5.87 | -1.34% | 2,682,600 |
| 23/04/24 | 5.95 | +2.06% | 3,676,050 |
| 22/04/24 | 5.83 | +0.52% | 1,317,900 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotes
Sirnaomics Ltd. is an investment holding company. The Company and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The Company is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a sterile drug product for the treatment of nonmelanoma skin cancer (NMSC), including squamous cell carcinoma in situ and basal cell carcinoma (BCC), recurrent keloids after keloidectomy, hypertrophic scar (HTS) and solid liver tumors, as well as for medical aesthetics. Its STP707 is a sterile drug product for the treatment of solid tumors, including liver cancer, metastatic cutaneous squamous-cell skin cancer (cSCC) and non-small cell lung cancer. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.
Calendar
27/08/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8048
USD
Average target price
9.231
USD
Spread / Average Target
+1,047.03%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -82.40% | 69.87M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 2257 Stock
